American Association for Cancer Research (AACR)

The American Association for Cancer Research (AACR) is the world's oldest and largest professional association related to cancer research. Based in Philadelphia, the AACR focuses on all aspects of cancer research, including basic, clinical, and translational research into the etiology, prevention, diagnosis, and treatment of cancer. Founded in 1907 by 11 physicians and scientists, the organization now has more than 42,000 members in over 120 countries. The mission of the AACR is to prevent and cure cancer through research, education, communication, collaboration, science policy and advocacy, and funding for cancer research.

Adjuvant atezolizumab extends disease-free survival after adjuvant chemotherapy compared with best supportive care after adjuvant chemotherapy in patients with resected stage II/IIIA non–small-cell lung cancer (NSCLC). Read More ›

Year in Review

2021 Midyear Review: Non–Small-Cell Lung Cancer

AACR & ASCO 2021 – Midyear Review

Every year, researchers and clinicians report on exciting advancements in the diagnosis and treatment of cancer. In 2021, despite the COVID-19 pandemic, developments in the management of lung cancer continue to be important and intriguing. Read More ›

Year in Review

Combination of Nivolumab and Chemotherapy in Nonmetastatic Resectable NSCLC (CheckMate-816)

AACR & ASCO 2021 – Midyear Review

Combining nivolumab with a limited course of chemotherapy in resectable non–small-cell lung cancer (NSCLC) enhances rates of pathologic complete response compared with chemotherapy alone. Read More ›

Year in Review

Phase 3 Study of Tislelizumab Compared with Docetaxel in Advanced NSCLC (RATIONALE 303)

AACR & ASCO 2021 – Midyear Review

Based on results of the RATIONALE 303 trial, tislelizumab significantly prolonged median overall survival by more than 5 months in patients with advanced non–small-cell lung cancer (NSCLC) compared with docetaxel. Read More ›

Year in Review

Acquired Resistance Mutations After Treatment of EGFR-Mutated Metastatic NSCLC with Osimertinib plus Savolitinib (TATTON)

AACR & ASCO 2021 – Midyear Review

Resistance to the combination of osimertinib plus savolitinib is predominantly mediated by acquired mutations in either MET, EGFR, or KRAS in patients with EGFR-mutated metastatic non–small-cell lung cancer (NSCLC). Read More ›

Year in Review

Safety Results of Phase 2 Study of Bintrafusp plus Chemotherapy in Advanced NSCLC (INTR@PID LUNG 024)

AACR & ASCO 2021 – Midyear Review

In patients with advanced squamous non–small-cell lung cancer (NSCLC), the combination of bintrafusp alfa and chemotherapy was well tolerated. The most common treatment-related adverse events were anemia, nausea, and pruritus. Read More ›

Year in Review

Randomized Phase 3 Study of Sintilimab versus Docetaxel in Advanced Squamous NSCLC (ORIENT-3)

AACR & ASCO 2021 – Midyear Review

Compared with docetaxel, sintilimab significantly prolonged median overall survival by more than 3 months in patients with advanced squamous non–small-cell lung cancer (NSCLC). Read More ›

Year in Review

Phase 1 Trial of VS-6766, a Dual RAF-MEK Inhibitor, and Defactinib, an FAK Inhibitor

AACR & ASCO 2021 – Midyear Review

In patients with non–small-cell lung cancer and KRAS G12V mutations who were pretreated with chemotherapy and immunotherapy, the combination of VS-6766 and defactinib is active with an acceptable tolerability profile. Read More ›

Year in Review

Phase 2 Study of DM-CHOC-PEN in Patients with NSCLC with Central Nervous System Involvement

AACR & ASCO 2021 – Midyear Review

In patients with non–small-cell lung cancer (NSCLC) that involves the central nervous system and who lack genetic rearrangements or tumor targets, DM-CHOC-PEN, a bis-alkylator of DNA, has produced long-term objective responses with manageable toxicities. Read More ›

Year in Review

Phase 2 Study of D-0316 in Patients with Advanced NSCLC and EGFR T790M Mutation

AACR & ASCO 2021 – Midyear Review

D-0316, a third-generation EGFR tyrosine kinase inhibitor (TKI), has antitumor activity and acceptable toxicity in patients with EGFR T790M–positive non–small-cell lung cancer (NSCLC) who progressed after EGFR-TKI treatment. Read More ›

American Association for Cancer Research (AACR)

Page 1 of 3